ArticleBJC reports2025
Treatment with checkpoint inhibitors for unresectable non-metastatic mismatch repair deficient intestinal cancer; a case series.
Article in BJC reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04014530 (Study of Pembrolizumab Combined With Ataluren In Patients With Metastatic pMMR and dMMR Colorectal Adenocarcinomas or Metastatic dMMR Endometrial Carcinoma), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of Pembrolizumab Combined With Ataluren In Patients With Metastatic pMMR and dMMR Colorectal Adenocarcinomas or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study
Who cites it
2 citing papers in PubMed.
- Metastatic Unfunctional Pancreatic Neuroendocrine Tumor in Lynch Syndrome.Clinical case reports · 2026Article
- Comprehensive Landscape of Diagnostic, Prognostic and Predictive Biomarkers in Colorectal Cancer: From Genomics to Multi-Omics Integration in Precision Medicine.Journal of personalized medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is a common malignancy, with mismatch repair deficient (dMMR) CRC comprising approximately 15% of non-metastatic cases. dMMR tumors generate neoantigens making them highly responsive to immune checkpoint inhibitors, this became the first-line treatment for metastatic dMMR CRC. Aim of this study is to evaluate the efficacy of single-agent Pembrolizumab for patients with locally advanced unresectable dMMR intestinal cancers.
methodsWe retrospectively reviewed patients with locally advanced unresectable dMMR/MSI-H CRC or small intestinal adenocarcinoma (SIA) who received PD-1 inhibitors between January 2022 and December 2023 at 1 University Medical Center and 3 regional hospitals and analyzed the treatment efficacy and survival outcomes.
resultsResponse rate was 78% after at least one cycle of Pembrolizumab with conversion to resection in nearly 40%. Patients who underwent primary tumor resection had a two-year overall survival (OS) of 100%, whereas those without resection had significantly lower OS (42%), progression-free survival (PFS; 36%), and cancer-specific survival (CSS; 71%) at two years. In total, 22% of the patients discontinued the treatment due to toxicity. DISCUSSION: Although the observed response rates of Pembrolizumab are high, there is still room for improvement. Dual immune checkpoint inhibitors might be needed for these patients to improve outcomes. CLINICAL
trial registrationA selection of patients included in this study were part of the ATAPEMBRO study, a single-centre, open label, phase 1-2 study (NCT04014530).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.